TY  - GEN
AU  - Hueber,Wolfgang
AU  - Sands,Bruce E
AU  - Lewitzky,Steve
AU  - Vandemeulebroecke,Marc
AU  - Reinisch,Walter
AU  - Higgins,Peter D R
AU  - Wehkamp,Jan
AU  - Feagan,Brian G
AU  - Yao,Michael D
AU  - Karczewski,Marek
AU  - Karczewski,Jacek
AU  - Pezous,Nicole
AU  - Bek,Stephan
AU  - Bruin,Gerard
AU  - Mellgard,Bjoern
AU  - Berger,Claudia
AU  - Londei,Marco
AU  - Bertolino,Arthur P
AU  - Tougas,Gervais
AU  - Travis,Simon P L
TI  - Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
SN  - 1468-3288
PY  - 2013///0114
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Anti-Inflammatory Agents
KW  - therapeutic use
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Bayes Theorem
KW  - Biomarkers
KW  - metabolism
KW  - Crohn Disease
KW  - drug therapy
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Genetic Markers
KW  - Humans
KW  - Infusions, Intravenous
KW  - Interleukin-17
KW  - antagonists & inhibitors
KW  - Leukocyte L1 Antigen Complex
KW  - Male
KW  - Middle Aged
KW  - Polymorphism, Single Nucleotide
KW  - Severity of Illness Index
KW  - Treatment Failure
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1136/gutjnl-2011-301668
ER  -